Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria

Blood

Volumn 118, Issue 15, 2011, Pages 4242-4249

  Arai, Sally ^a   Jagasia, Madan ^b   Storer, Barry ^c   Chai, Xiaoyu ^c   Pidala, Joseph ^d   Cutler, Corey ^e   Arora, Mukta ^f   Weisdorf, Daniel J ^f   Flowers, Mary E D ^c   Martin, Paul J ^c   Palmer, Jeanne ^g   Jacobsohn, David ^h   Pavletic, Steven Z ⁱ   Vogelsang, Georgia B ^j   Lee, Stephanie J ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; SCORING SYSTEM; SURVIVAL;

EID: 80054090049     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-344390     Document Type: Article

References (22)

1. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414. (Pubitemid 34761100)
2. Pidala J, Kurland B, Chai X, et al. Patient reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
3. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217. (Pubitemid 10036817)
4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
5. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006;12(2):126-137. (Pubitemid 43138008)
6. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2006;12(3):252-266. (Pubitemid 43273710)
7. Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2010;16(1):53-61.
8. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12):2459-2464. (Pubitemid 20202328)
9. Ringden O, Paulin T, Lonnqvist B, Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol. 1985;13(10):1062-1067. (Pubitemid 16172301)
10. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98(4):461-466. (Pubitemid 13116613)
11. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97(5):1219- 1226. (Pubitemid 32183742)
12. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9(1):38-45. (Pubitemid 41123052)
13. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus- host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
14. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501-3506. (Pubitemid 39564419)
15. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-708.
16. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74(4):1428-1435. (Pubitemid 19227458)
17. Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant. 2007;13(10):1207-1215. (Pubitemid 47413020)
18. Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43(2):149-153.
19. Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78-84.
20. Kim DY, Lee JH, Kim SH, et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant. 2010;45(7):1174-1180.
21. Perez-Simon JA, Encinas C, Silva F, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14(10):1163-1171.
22. Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11):1852-1858.